Yesid Alvarado

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689

N/A

3.9DataRank · unranked

158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122

N/A

1.4DataRank · unranked

25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Blood Advances(2024)10.1182/bloodadvances.2024014633

N/A

0.420DataRank · unranked

9 citations

Danielle M. Brander, Yesid Alvarado, Catherine Diefenbach, Daniel Nathan Egan, Shira Dinner +14 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675

N/A

0.308DataRank · unranked

5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100108

N/A

0.173DataRank · unranked

2 citations

Rachel J. Cook, Shira Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi‐Sharifi +9 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037

N/A

0DataRank · unranked

20 citations

Koji Sasaki, Aram Bidikian, Ghayas C. Issa, Tapan M. Kadia, Nitin Jain +11 more

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more